Simulations Plus - SLP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.00
  • Forecasted Upside: 30.50 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$49.81
▲ +1.27 (2.62%)

This chart shows the closing price for SLP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Simulations Plus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLP

Analyst Price Target is $65.00
▲ +30.50% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Simulations Plus in the last 3 months. The average price target is $65.00, with a high forecast of $70.00 and a low forecast of $60.00. The average price target represents a 30.50% upside from the last price of $49.81.

This chart shows the closing price for SLP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Simulations Plus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2022Raymond JamesBoost TargetOutperform$54.00 ➝ $70.00Low
7/7/2022Craig HallumBoost TargetBuy$55.00 ➝ $60.00N/A
1/4/2022SidotiInitiated CoverageNeutral ➝ NeutralHigh
10/26/2021Craig HallumUpgradeHold ➝ Buy$65.00 ➝ $53.00High
7/13/2021OppenheimerReiterated RatingBuy$75.00High
7/13/2021Craig HallumLower TargetHold$74.00 ➝ $65.00High
7/13/2021Raymond JamesLower TargetOutperform$95.00 ➝ $54.00High
4/13/2021Craig HallumLower TargetHold$81.00 ➝ $74.00High
1/12/2021OppenheimerBoost Target$79.00 ➝ $85.00High
1/12/2021Craig HallumDowngradeBuy ➝ HoldHigh
11/25/2020Taglich BrothersUpgradeSpeculative Buy ➝ Buy$76.00High
11/17/2020Craig HallumBoost TargetBuy$75.00 ➝ $81.00High
10/16/2020Raymond JamesInitiated CoverageOutperform$95.00Low
9/8/2020OppenheimerInitiated CoverageOutperform$79.00High
7/10/2020Craig HallumBoost TargetBuy$56.00 ➝ $75.00High
6/8/2020Craig HallumBoost TargetBuy$40.00 ➝ $56.00Low
1/6/2020Craig HallumInitiated CoverageBuy$40.00High
1/16/2019Taglich BrothersDowngradeBuy ➝ Speculative BuyMedium
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/4/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Read More

Today's Range

Now: $49.81
Low: $48.43
High: $50.33

50 Day Range

MA: $58.99
Low: $47.75
High: $66.88

52 Week Range

Now: $49.81
Low: $35.18
High: $67.59

Volume

130,238 shs

Average Volume

125,246 shs

Market Capitalization

$1.01 billion

P/E Ratio

87.39

Dividend Yield

0.49%

Beta

0.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Simulations Plus?

The following equities research analysts have issued stock ratings on Simulations Plus in the last twelve months: Craig Hallum, Raymond James, Sidoti, StockNews.com, and TheStreet.
View the latest analyst ratings for SLP.

What is the current price target for Simulations Plus?

2 Wall Street analysts have set twelve-month price targets for Simulations Plus in the last year. Their average twelve-month price target is $65.00, suggesting a possible upside of 30.5%. Raymond James has the highest price target set, predicting SLP will reach $70.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $60.00 for Simulations Plus in the next year.
View the latest price targets for SLP.

What is the current consensus analyst rating for Simulations Plus?

Simulations Plus currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLP will outperform the market and that investors should add to their positions of Simulations Plus.
View the latest ratings for SLP.

What other companies compete with Simulations Plus?

Other companies that are similar to Simulations Plus include IonQ, Agilysys, Telos, Ebix and Unisys. Learn More about companies similar to Simulations Plus.

How do I contact Simulations Plus' investor relations team?

Simulations Plus' physical mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company's listed phone number is (661) 723-7723 and its investor relations email address is [email protected] The official website for Simulations Plus is www.simulations-plus.com. Learn More about contacing Simulations Plus investor relations.